Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
FU0BXkjtztUV6gBy